Fenofibrate may reduce CVD risk in type 2 diabetes
Fenofibrate might reduce the risk of cardiovascular events in people with type 2 diabetes who have high levels of triglycerides and low levels of ‘good’ cholesterol despite being treated with statins, a study has found.
The treatment is primarily used to help reduce elevated levels of triglycerides, or fat, in the blood, but researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.
People with type 2 diabetes are at high risk of cardiovascular-related events, such as heart attacks, stroke, and even death, often because their levels of triglycerides are so high, and their high-density lipoprotein (HDL) cholesterol levels are low.
The study, funded by the US-based National Heart, Lung, and Blood Institute (NHLBI), saw the researchers follow 4,640 participants from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study for five years after the conclusion of the trial in 2009.
The findings, published in JAMA Cardiology, suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels. However, a randomized study is needed to confirm these findings, according to the authors.
The researchers concluded: “The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol.”
To access the paper, click here.